Skip to Content

News Release

Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2020

November 3, 2020 at 6:30 AM EST

BANNOCKBURN, Ill., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2020.

Given the merger between HC Group Holdings II, Inc. (“Option Care”) and BioScrip, Inc. (“BioScrip”) to form Option Care Health on August 6, 2019, comparisons to historical periods are relative to legacy Option Care only and incorporate BioScrip results from August 6, 2019 prospectively. Further, as reported on February 3, 2020, the Company completed a reverse 1-for-4 stock split in the first quarter and, as a result, all per share data below is reported incorporating the effect of the reverse stock split as if it was effective for all periods reported.

Third Quarter 2020 Financial Highlights

  • Net revenue of $781.6 million, up 27% compared to $615.9 million in the third quarter of 2019
  • Gross profit of $174.2 million, or 22.3% of net revenue, up 26% compared to $137.8 million, or 22.4% of revenue, in the third quarter of 2019
  • Net income of $1.7 million, or $0.01 per share, compared to net loss of $42.8 million, or $0.26 loss per share, in the third quarter of 2019
  • Adjusted EBITDA of $59.2 million, up 70% compared to $34.8 million in the third quarter of 2019
  • Cash flow from operations of $48.3 million compared to a cash outflow of $5.8 million in the third quarter of 2019
  • Cash balances of $140.0 million at the end of the third quarter and no outstanding borrowings on the Company’s $175.0 million revolver
  • Subsequent to the third quarter, the Company entered into new, multi-year national provider contracts with both Centene and Cigna

Comparable revenue growth for the quarter is approximately 13% when considering the impact and timing of the merger as well as harmonization of accounting policies, with chronic therapies growth over prior year in the mid teens and acute therapies flat to prior year. Additionally, the Company continues to make significant progress on merger-related integration efforts and expects to be complete with integration efforts, other than technology harmonization, by the end of the year.

John C. Rademacher, Chief Executive Officer, commented, “The third quarter was very productive for Option Care Health as we continue to serve patients relying on us for critical infusion therapies while also laying the foundation for sustained organic growth. Despite a very challenging operating environment, the team continues to rise to the challenge and reinforce the reliability and dedication of the Option Care team.”

Update on the Impact of the COVID-19 Pandemic

The COVID-19 pandemic continues to have a significant impact on the Company’s operations.  New patient referrals increased relative to the second quarter for both acute and chronic therapies and referral levels overall in the third quarter exceed pre-Covid levels.  Chronic patient referrals showed the largest improvement in the quarter, as patient migrations to treatment in the home or alternate site continued and referrals for newer therapies also increased.  Option Care Health continues to incur higher expenses related to both the procurement of personal protection equipment and medical supplies as well as with respect to its clinical labor.

As previously disclosed, as part of the Coronavirus Aid, Relief, and Economics Security Act (the “Cares Act”), the Company received approximately $11.7 million from the Public Health and Social Services Emergency Fund in the second quarter which it fully returned in the third quarter.  The cash receipt was reflected in the second quarter results as a cash inflow from financing activities and subsequently as a cash outflow from financing activities in the third quarter. There was no impact on the Company’s results from operations related to the receipt and return of the funds.

Full Year 2020 Guidance

For the full year, the Company expects to generate between $216 million and $220 million in Adjusted EBITDA and at least $80 million in free cash flow, defined by the Company as net change in ending cash balance compared to the cash balance at December 31, 2019.

Conference Call

The Company will host a conference call this morning at 8:30 a.m. E.T. which can be accessed by dialing (866) 360-3136 for U.S. participants, or (602) 563-8603 for international participants, and referencing conference ID 1576317; or via a live audio webcast that will be available online at A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 5,000 teammates, including approximately 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and teammates. To learn more, please visit our website at

Investor Contacts

Mike Shapiro Bob East, Asher Dewhurst, Jordan Kohnstam
Chief Financial Officer Westwicke
T:  (312) 940-2538 T:  (413) 213-0500

Forward-Looking Statements - Safe Harbor

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation; (iv) the loss of one or more key payers; and (v) the spread and impact of the COVID-19 pandemic. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, and restructuring, integration and other expenses. As part of restructuring, integration and other expenses, the Company may incur significant charges such as the write down of certain long−lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health’s business operations and facilitates comparisons to the Company’s historical operating results. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see the attachment to this earnings release.

  Schedule 1



  September 30,   December 31,
  2020   2019
Cash and cash equivalents $ 140,047     $ 67,056  
Accounts receivable, net 320,920     324,416  
Inventories 155,478     115,876  
Prepaid expenses and other current assets 60,030     51,306  
Total current assets 676,475     558,654  
Property and equipment, net 113,017     133,198  
Intangible assets, net 359,766     385,910  
Goodwill 1,428,610     1,425,542  
Other noncurrent assets 90,622     86,243  
Total noncurrent assets 1,992,015     2,030,893  
TOTAL ASSETS $ 2,668,490     $ 2,589,547  
Accounts payable $ 290,206     $ 221,060  
Other current liabilities 142,967     108,944  
Total current liabilities 433,173     330,004  
Long-term debt, net of discount, deferred financing costs and current portion 1,162,836     1,277,246  
Other noncurrent liabilities 78,985     75,470  
Total noncurrent liabilities 1,241,821     1,352,716  
Total liabilities 1,674,994     1,682,720  
STOCKHOLDERS’ EQUITY 993,496     906,827  

Schedule 2



  Three Months Ended
September 30,
  Nine Months Ended
September 30,
  2020   2019   2020   2019
NET REVENUE $ 781,609     $ 615,880     $ 2,227,897     $ 1,589,638  
COST OF REVENUE 607,456     478,107     1,729,395     1,252,281  
GROSS PROFIT 174,153     137,773     498,502     337,357  
Selling, general and administrative expenses 123,000     133,475     377,198     315,815  
Depreciation and amortization expense 16,597     16,023     54,892     36,142  
Total operating expenses 139,597     149,498     432,090     351,957  
OPERATING INCOME (LOSS) 34,556     (11,725 )   66,412     (14,600 )
OTHER INCOME (EXPENSE):              
Interest expense, net (24,583 )   (21,509 )   (84,102 )   (44,117 )
Other, net (7,554 )   (5,984 )   (5,958 )   (4,661 )
Total other expense (32,137 )   (27,493 )   (90,060 )   (48,778 )
INCOME (LOSS) BEFORE INCOME TAXES 2,419     (39,218 )   (23,648 )   (63,378 )
INCOME TAX EXPENSE (BENEFIT) 756     3,576     2,267     (3,269 )
NET INCOME (LOSS) $ 1,663     $ (42,794 )   $ (25,915 )   $ (60,109 )
Earnings (loss) per share, basic and diluted $ 0.01     $ (0.26 )   $ (0.14 )   $ (0.40 )

Schedule 3



  Nine Months Ended
September 30,
  2020   2019
Net loss $ (25,915 )   $ (60,109 )
Adjustments to reconcile net loss to net cash provided by operations:      
Depreciation and amortization expense 60,054     38,997  
Other non-cash adjustments 39,503     21,446  
Changes in operating assets and liabilities:      
Accounts receivable, net 3,496     71,029  
Inventories (39,602 )   (6,212 )
Accounts payable 66,508     (36,157 )
Other (2,316 )   (12,424 )
Net cash provided by operating activities 101,728     16,570  
Acquisition of property and equipment (12,871 )   (13,150 )
Other investing cash flows 541     636  
Business acquisitions, net of cash acquired     (700,170 )
Net cash used in investing activities (12,330 )   (712,684 )
Proceeds from debt     981,050  
Retirement of debt obligations (125,000 )   (226,738 )
Net proceeds from issuance of common stock 118,934      
Deferred financing costs     (36,538 )
Other financing cash flows (10,341 )   (5,262 )
Net cash (used in) provided by financing activities (16,407 )   712,512  
Cash and cash equivalents - beginning of the period 67,056     36,391  
CASH AND CASH EQUIVALENTS - END OF PERIOD $ 140,047     $ 52,789  

Schedule 4



  Three Months Ended 
 September 30,
  Nine Months Ended
September 30,
  2020   2019   2020   2019
Consolidated net income (loss) $ 1,663     $ (42,794 )   $ (25,915 )   $ (60,109 )
Interest expense, net 24,583     21,509     84,102     44,117  
Income tax expense (benefit) 756     3,576     2,267     (3,269 )
Depreciation and amortization expense 18,241     17,407     60,054     38,997  
Consolidated EBITDA 45,243     (302 )   120,508     19,736  
EBITDA adjustments              
Accounting principle changes and non-cash charges     4,277         8,535  
Stock-based incentive compensation 1,170     2,745     2,588     3,898  
Loss on extinguishment of debt 8,349     5,469     8,349     5,469  
Restructuring, acquisition, integration and other 4,461     22,585     22,580     40,151  
Consolidated adjusted EBITDA $ 59,223     $ 34,774     $ 154,025     $ 77,789  


Source: Option Care Health, Inc.